Oncology Hour is a live podcast series that addresses common questions and topics in the cancer community such as cancer treatment options, clinical trials, overview of cancer types, and more featuring Massive Bio team members and Oncology experts. Oncology Hour is hosted by Massive Bio, whose mission is to provide all people with equal access to leading edge therapies and new-emerging clinical trials, regardless of where th ...
... Read more
Episode 11 of the Oncology Hour Podcast features a conversation with John Hallick on Lung cancer, MET mutations, and why patients should be aware of biomarker testing and clinical trial options. John Hallick is a lung cancer survivor and founder of the MET Crusaders, who are a community of lung cancer patients, care givers, advocates, researchers, and physicians dedicated to helping patients with the MET alteration live normal lives.
On episode 10 of Oncology Hour, we are talking about all things pancreatic cancer with Massive Bio Co-Founder and oncologist, Dr. Arturo Loaiza-Bonilla, MD, MSEd, FACP. During the episode, a variety of pancreatic cancer topics are covered including diagnosis, treatment options, testing, and clinical research.
How Genetics Impact Pediatric Cancer Clinical Trials is the 9th episode of the Oncology Hour Podcast featuring pediatric oncologists Dr. Jason Freedman and Dr. Ted Laetsch. Host Fiona Evans asks questions to gain a better understanding of the importance of biomarkers in cancer treatment, Common biomarkers in pediatric cancer, genomic testing for clinical trials, and more.
On episode 8 of Oncology Hour, we discuss ALK alterations in cancer and genomic testing. ALK Alterations appear in lung cancer, lymphoma, and childhood cancer. ALK inhibitors are treatments that target ALK alterations in cancer patients. Today's guests are pediatric oncologists Dr. Jason Freedman and Dr. Ted Laetsch. Dr. Jason Freedman specializes in pediatric oncology and has contributed to the development of clinical guidelines to standardize management of symptoms. Dr Ted Laetsch leads clinical and translational research evaluating novel targeted and immunotherapies for children with high-risk and often ultra-rare cancers.
On Episode 7 of Oncology Hour, we discuss Marginal Zone Lymphoma (MZL) with oncologist and lymphoma specialist Dr. Mayur Narkhede. Dr. Narkhede reviews different topics on this common Non-Hodgkin Lymphoma (NHL) such as treatment options, clinical trials, and differences from other types of lymphoma.